Nature Biotechnology Contents: Volume 32 pp 1 - 108

If you are unable to see the message below, click here to view.

Advertisement Frontiers in Bioengineering and Biotechnology Research Topics are a great opportunity for you to highlight your research focus by creating an online dialogue on a focused research area, with manuscripts encompassing recent advancements, the latest methods, opinions, and more. Our platform makes launching and managing a Research Topic a straightforward process and you will have the full support of the Frontiers editorial office through every step. Find out more on how to suggest a Research Topic TABLE OF CONTENTS January 2014 Volume 32, Issue 1 Editorial News Bioentrepreneur Opinion and Comment Features News and Views Computational Biology Research Careers and Recruitment Subscribe   Facebook   RSS   Recommend to library   Twitter   Advertisement BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities   Advertisement 8th annual Salk Institute, Fondation IPSEN, and Nature Symposium on Biological Complexity: Genes and Physiology January 29-31, 2014 Salk Institute for Biological Studies La Jolla, CA, USA  Click here for more information or to register for this conference today!     Editorial Top Irresistible force meets immoveable object   p1 doi:10.1038/nbt.2805 The US Food and Drug Administration (FDA) must clarify how it intends to enforce device regulation on direct-to-consumer (DTC) services that offer to interpret genome variation. News Top FDA approvals usher in the post-interferon era in HCV   pp3 - 5 Cormac Sheridan doi:10.1038/nbt0114-3 Sequenom falls after judge invalidates Down's patent   p5 Emily Waltz doi:10.1038/nbt0114-5 NextCODE to mine Icelandic genetic wealth   p6 Emma Dorey doi:10.1038/nbt0114-6a Genentech's glyco-engineered antibody to succeed Rituxan   pp6 - 7 Mark Ratner doi:10.1038/nbt0114-6b 10,000 rare-disease genomes sequenced   p7 Nuala Moran doi:10.1038/nbt0114-7 23andMe's designer baby patent   p8 Laura DeFrancesco doi:10.1038/nbt0114-8 Pfizer and Lilly shoulder novel pain-drug risks   p9 Gunjan Sinha doi:10.1038/nbt0114-9b FDA halts then allows sales of Ariad's leukemia medication   pp9 - 11 Melanie Senior doi:10.1038/nbt0114-9a Millionaire's gift to San Diego   p10 Lucas Laursen doi:10.1038/nbt0114-10a FDA tows personalized line   p10 Emily Waltz doi:10.1038/nbt0114-10b Around the world in a month   p11 doi:10.1038/nbt0114-11 News Feature Companion therapeutics   pp12 - 14 Gunjan Sinha doi:10.1038/nbt.2793 A growing market for therapeutic drugs to treat pets is fostering a startup boom. Gunjan Sinha reports. Bioentrepreneur Top Building a business The view beyond venture capital   pp15 - 23 Dennis Ford and Barbara Nelsen doi:10.1038/nbt.2780 Podcast First Rounders Podcast: Harvey Berger   p23 doi:10.1038/nbt0114-23 Opinion and Comment Top Correspondence Basic research is often best appreciated in retrospect   pp24 - 25 Henry I Miller doi:10.1038/nbt.2784 GM food in the public mind—facts are not what they used to be   p25 Morten Andreasen doi:10.1038/nbt.2790 The necessity of GM food for India   pp25 - 26 G. Padmanaban doi:10.1038/nbt.2791 Commentary A cancer trial scandal and its regulatory backlash   pp27 - 31 Razelle Kurzrock, Hagop Kantarjian and David J Stewart doi:10.1038/nbt.2792 Regulatory fallout from a scandal surrounding the fabrication of data used to support a molecular test in a Duke University cancer trial is exacting an unjustifiable toll not only on health economics but also on patient lives. Features Top What's fueling the biotech engine—2012 to 2013   pp32 - 39 Saurabh (Rob) Aggarwal doi:10.1038/nbt.2794 Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until biologics' last hurrah? Clinical development success rates for investigational drugs   pp40 - 51 Michael Hay, David W Thomas, John L Craighead, Celia Economides and Jesse Rosenthal doi:10.1038/nbt.2786 The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates. NIH inventions translate into drugs and biologics with high public health impact   pp52 - 58 Sabarni K Chatterjee and Mark L Rohrbaugh doi:10.1038/nbt.2785 Compared with other US public-sector research institutions, the US National Institutes of Health has contributed inventions that have had a disproportionately greater impact on the overall number of products produced, drugs granted orphan status and drugs granted priority review. Patents Biotech patents and science policy: the Spanish experience   pp59 - 61 Ignacio Belda, Gerardo Penas, Alejandro Alonso, Domingo Marquina, Eva Navascues et al. doi:10.1038/nbt.2781 In an environment of crisis and cuts, innovative patent management strategies may offer a way for countries to improve return on R&D investment. Recent patent applications in agricultural microbes   p62 doi:10.1038/nbt.2804 News and Views Top Cytokine-driven beta-cell production in vivo    pp63 - 64 Hannah N Worchel and Mark A Magnuson doi:10.1038/nbt.2788 Transient treatment of diabetic mice with two cytokines induces acinar-to-beta-cell conversion to an extent sufficient to durably restore normoglycemia. See also: Research by Baeyens et al. Plant pest destruction goes viral   pp65 - 66 Anna E Whitfield, Dorith Rotenberg and Thomas L German doi:10.1038/nbt.2787 Fusion of a viral coat protein to an insect-specific neurotoxin delivers the molecule into aphids where it is insecticidal. See also: Research by Bonning et al. Collateral damage   pp66 - 68 Robert E W Hancock doi:10.1038/nbt.2779 Wiser use of antibiotics could help combat the emergence of drug-resistant pathogens. Naivete of the human pluripotent stem cell   pp68 - 70 Victoria L Mascetti and Roger A Pedersen doi:10.1038/nbt.2789 Human pluripotent stem cells can be stabilized in a state resembling the inner cell mass of the blastocyst. Research Highlights   p70 doi:10.1038/nbt.2801 Biotechnology JOBS of the week Senior Researcher – Emerging Fields Industrial Biotechnology ACIB (Austrian Centre of Industrial Biotechnology) Postdoc in Experimental RNA Biochemistry University of Vienna (Universitaet Wien) Professor of Biochemistry Swedish University of Agricultural Sciences (SLU) PhD in Molecular Biology and Bioinformatics Universität Basel Postdoctoral Positions in Computational Biology and Bioinformatics University of Alabma, Birmingham More Science jobs from Biotechnology EVENT Staying on the Cutting Edge of Biotechnology Patent Searching February 24, 2014 Cambridge, USA More science events from Computational Biology Top Analysis Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair   pp71 - 75 Paz Polak, Michael S Lawrence, Eric Haugen, Nina Stoletzki, Petar Stojanov et al. doi:10.1038/nbt.2778 Polak et al. analyze somatic mutations and chromatin accessibility data to gain insight into mutational processes in cancer genomes. Research Top Articles Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice   pp76 - 83 Luc Baeyens, Marie Lemper, Gunter Leuckx, Sofie De Groef, Paola Bonfanti et al. doi:10.1038/nbt.2747 Short-term treatment with cytokines reprograms acinar cells into beta cells and restores durable normoglycemia in diabetic mice. See also: News and Views by Worchel & Magnuson Efficient generation of lung and airway epithelial cells from human pluripotent stem cells   pp84 - 91 Sarah X L Huang, Mohammad Naimul Islam, John O'Neill, Zheng Hu, Yong-Guang Yang et al. doi:10.1038/nbt.2754 A new protocol enables efficient differentiation of human pluripotent stem cells to lung cells, including type II alveolar epithelial cells. Letters Genome-wide localization of small molecules   pp92 - 96 Lars Anders, Matthew G Guenther, Jun Qi, Zi Peng Fan, Jason J Marineau et al. doi:10.1038/nbt.2776 A new method called Chem-seq reveals the genomic binding sites of drugs that target DNA and chromatin. Directed evolution of genetic parts and circuits by compartmentalized partnered replication   pp97 - 101 Jared W Ellefson, Adam J Meyer, Randall A Hughes, Joe R Cannon, Jennifer S Brodbelt et al. doi:10.1038/nbt.2714 A PCR-based directed evolution method facilitates selection of synthetic biology circuits and parts with desired functionality. Toxin delivery by the coat protein of an aphid-vectored plant virus provides plant resistance to aphids   pp102 - 105 Bryony C Bonning, Narinder Pal, Sijun Liu, Zhaohui Wang, S Sivakumar et al. doi:10.1038/nbt.2753 A viral protein delivers a toxin from an insect's gut to its body cavity, providing a new strategy for controlling sap-sucking agricultural pests. See also: News and Views by Whitfield et al. Careers and Recruitment Top On being a professional mutant   pp106 - 107 Gayatri Saberwal doi:10.1038/nbt.2796 Systematic attention is required to confront the challenges faced by life scientists in interdisciplinary professions in India. People People   p108 doi:10.1038/nbt.2803 Top Advertisement nature.com webcasts  Nature Protocols presents a webcast on: Transformative Technologies in Neuroscience: Optogenetics Thursday January 23 at 9am PST / 12pm EST / 5pm GMT / 6pm CET  Register for the free webcast followed by our live Q & A session  This material is based upon work supported by the National Science Foundation under Grant No. 1348284.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.